Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 326

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 326
---
.03 per share, respectively. Unrecognized share-based compensation for stock options as of December 31, 2024 was $45.9 million, which is expected to be recognized over a weighted-average period of 2.1 years.
The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following assumptions:

        Year EndedDecember 31,

        2024

        2023
         
        2022

        Expected term (in years)
         
        5.27 - 6.74

        5.27 - 6.25
         
        2.92 - 6.33

        Expected volatility
         
        68.27% - 70.57%

        68.74% - 81.98%
         
        65.20% - 81.68%

        Risk-free interest rate
         
        3.43% - 4.47%

        3.47% - 4.67%
         
        1.47% - 4.37%

        Expected dividend yield

        —

        —
         
        —
       
      Restricted Stock UnitsThe following table provides a summary of restricted stock units activity under the 2021 Plan during the year ended December 31, 2024:

        Number ofShares

        Weighted AverageGrant Date Fair ValuePer Share

        Unvested restricted stock units at December 31, 2023

        1,031,545

        $
        18.27

        Granted

        1,640,180

        $
        14.35

        Vested

        (680,963
        )
         
        $
        16.48

        Forfeiture

        (216,475
        )
         
        $
        16.22

        Unvested restricted stock units at December 31, 2024

        1,774,287

        $
        15.58

      Unamortized share-based compensation for restricted stock units as of December 31, 2024 was $25.8 million, which is expected to be recognized over a weighted-average period of 2.7 years.

F-32

Restricted Stock AwardsThe following table provides a summary of the unvested common stock awards activity during the year ended December 31, 2024.

        Number ofShares